Leidos, Inc.

Ramses Ayala

James Pannucci

Gabriel M Gutierrez

Vinayaka Kotraiah

This disclosure provides peptides which have a strong affinity for the checkpoint receptor 'programmed death 1' (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.

PD-1 peptide inhibitors

This disclosure provides peptides which have a strong affinity for the checkpoint receptor 'programmed death 1' (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.

Growing community of inventors

Reston, VA, United States of America

Ramses Ayala